<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/><br/>SYNH +24.6%, AAXN +22.5%, ETSY +16.2%, OCN +14.2%, TIVO +12.9%, (also announces plan to explore all alternatives to maximize shareholder value), ENPH +11.1%, WTW +10.3%, TAST +9.3%, BKNG +8.4%, RRD +8.2%, FRAN +7.1%, MGIC +7%, CSU +6.6%, CGBD +6.5%, SBLK +6.1%, OAS +5.8%, ATSG +5.8%, VEEV +5.5%, CHS +5%, DAR +4.8%, RP +3.7%, MASI +3.4%, PNM +3.4%, HEI +3.1%, AKAO +3.1%, MTZ +3%, SUPN +3%, UNVR +3%, ATUS +2.8%, FSS +2.5%, UPL +2.4%, FRO +2%, IMAX +1.9%, ESRX +1.8%, RDC +1.8%, XOG +1.7%, DEPO +1.6%, STWD +1.6%, GBT +1.3%, WP +1.3%, MITT +1%, PEN +1%, ODP +1%, .<br/><b>M&A news:</b><br/><br/>STB +24% (Student Transportation to be acquired by a group of investors led by CDPQ for US$7.50 per common share in cash)<br/>PHH +23.7% (PHH Corp to be acquired by Ocwen (OCN) in an all cash transaction valued at $360 million, or $11.00 per fully-diluted share)<br/>OCN +14.2% (PHH Corp to be acquired by Ocwen (OCN) in an all cash transaction valued at $360 million, or $11.00 per fully-diluted share)<br/>SGYP +8.5% (acquires exclusive Canadian rights to FDA-Approved Trulance from Synergy Pharmaceuticals)<br/>MON +0.9% (Monsanto merger with Bayer (BAYRY) said to be set to be approved by the EU, subject to conditions, according to Reuters)<br/><b>Other news:</b><br/><br/>CODX +14.7% (positive results from Co-Primers Technology in multiplex test for SNP detection)<br/>MTP +11.1% (European Medicines Agency has granted Orphan Drug Designation for its advanced liver cancer drug candidate MTD119)<br/>HTBX +6.7% (announces 'positive' interim data from its Phase 2 clinical trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer)<br/>MBVX +5.6% (reports positive safety results from initial cohort of MVT-1075 Radioimmunotherapy Phase 1 Trail for the treatment of Pancreatic, Colon and Lung Cancers)<br/>ECYT +3.6% (proposed public offering of common stock)<br/>EXPE +2.6% (following BKNG results)<br/>NMIH +1.5% (prices 3.7 mln shares of common stock at $19.75 per share)<br/>DPW +1.2% (reschedules investor webcast to March 15 at 5pm ET - originally set for February 21 - focus of the webcast will be on MTIX)<br/>STMP +1% (hired former Mattel Chief Technology Officer Jonathan Bourgoine as its new Chief Technology Officer)<br/>BEDU +1% (prices 10 mln ADS's at $19.00 per ADS)<br/>SHPG +1% (receives FDA acceptance of BLA for Cal-PEG)<br/>BIDU +0.8% (Baidu.com's iQiyi unit filed for $1.5 bln IPO late yesterday)<br/><b>Analyst comments:</b><br/><br/>MELI +3.8% (upgraded to Overweight from Neutral at JP Morgan)<br/>CVX +1.1% (upgraded to Buy from Neutral at BofA/Merrill)<br/>ADM +0.9% (upgraded to Buy from Neutral at Buckingham Research)<br/>PM +0.7% (upgraded to Buy from Neutral at Citigroup)<br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/><br/>FTR -24.8%, (also suspends the quarterly cash dividend on the common stock), ELF -10.8%, TSRO -9.2%, VRX -8.3%, ACAD -7.6%, BGFV -7.6%, BGS -7.1%, MNKD -7%, LOW -6.7%, GTE -6.1%, ALRM -5.8%, EOG -5.6%, PZZA -5.1%, GGB -4.7%, ROG -4.5%, SSYS -4%, HTZ -3.9%, TA -3.8%, JONE -3.1%, SSW -3.1%, CYH -2.9%, MHLD -2.8%, TDOC -2.7%, TNET -2.6%, JAZZ -2.6%, WDAY -2.3%, VTVT -2.3%, (also files for $250 mln share Class A common stock shelf offering ), CROX -2.3%, DXCM -2.2%, SQ -1.7%, DRYS -1.1%, FGEN -0.8%<br/><b>Other news:</b><br/><br/>ATRA -6.6% (proposed offering of $150 mln in shares of common stock)<br/>CELG -6.1% (receives Refusal to File letter from the FDA regarding its New Drug Application for ozanimod in development for the treatment of patients with relapsing forms of multiple sclerosis)<br/>GM -1.5% (General Motors announced 40 mln share secondary offering of common stock by the UAW Retiree Medical Benefits Trust; GM intends to repurchase a portion of the shares being offered)<br/>DISCA -1.3% (still checking - DISCA / SNI set election deadline - expect to consummate the transactions contemplated by the Merger Agreement on March 6, 2018)<br/>DM -0.8% (files for $500 mln common units representing limited partner interests shelf offering)<br/><b>Analyst comments:</b><br/><br/>ALV -1.5% (downgraded to Sell from Hold at Societe Generale)<br/><br/>Briefing.com